Insight Molecular Diagnostics Inc. (IMDX)

Nasdaq Pharmaceutical Diagnostics SIC: 2835
D
Pipeline Grade

Financial Position (from SEC Filings)

$19.1M
Cash & Equivalents
$7.6M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$164M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2027-05-01 Phase1 Readout —

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IMDX.

SEC EDGAR Filings

All SEC filings for Insight Molecular Diagnostics Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.